Skip to main content
Fig. 3 | Journal of Experimental & Clinical Cancer Research

Fig. 3

From: PARP inhibitor veliparib and HDAC inhibitor SAHA synergistically co-target the UHRF1/BRCA1 DNA damage repair complex in prostate cancer cells

Fig. 3

Co-administration of SAHA and veliparib synergistically decreased PCa colony formation. Prostate cancer and non-malignant prostate epithelial cells were treated with SAHA (0.5 uM) and veliparib (10 uM) alone or in combination for 7 days. The cell colonies were stained by crystal violet assay. A representative image is shown. The number of cell colonies was counted. Mean relative percent of clone number ± SD is shown.*p < 0.05;**p < 0.01 (SAHA or veliparib alone vs. co-treatment). a LNCAP. b C4–2. c VCaP. d CWR22Rv1. e PC-3. f DU145. g RWPE-1

Back to article page